Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BBSome-interacting protein 1 (BBIP1, also known as BBS18 or BBSome-interacting protein of 10 kDa) is the smallest subunit in the core of the BBSome, an octameric protein complex essential for the formation and function of primary cilia in eukaryotic cells[1][4]. BBIP1 serves as a critical structural scaffold within the BBSome core complex, winding through tetratricopeptide repeat (TPR) domains of the subunits BBS4 and BBS8, and stabilizing their interactions[1][4]. The BBSome acts as a cargo adapter for targeting specific signaling receptors to the ciliary membrane, and disruption of BBIP1 impairs BBSome assembly, cilia formation, and stability, leading to Bardet–Biedl syndrome, a multisystemic genetic ciliopathy[1][4]. BBIP1 is not a direct therapeutic target, receptor, or enzyme; rather, it is a vital structural protein essential for BBSome integrity and thus proper ciliary signaling. There are currently no drugs known to specifically target BBIP1, nor is it used as a direct clinical biomarker or therapeutic target[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BBSome-interacting protein 1 (BBIP1).